These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38603817)

  • 1. Exploring the effects of Factor Xa inhibitors on thrombin generation in people with haemophilia.
    Dix C; McFadyen JD; Tran HA
    Thromb Res; 2024 May; 237():148-153. PubMed ID: 38603817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
    Siddiqui F; Tafur A; Ramacciotti LS; Jeske W; Hoppensteadt D; Ramacciotti E; Iqbal O; Fareed J
    Clin Appl Thromb Hemost; 2019; 25():1076029619863493. PubMed ID: 31298056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of direct factor IIa and factor Xa inhibitors in protein C-deficient plasma detected using thrombin generation and viscoelastometry assays.
    Aungraheeta R; FitzGibbon L; Reilly-Stitt C; Mumford AD
    Int J Lab Hematol; 2020 Apr; 42(2):126-133. PubMed ID: 31756037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of thrombin generation with St Genesia to evaluate xaban pharmacodynamics: Analytical performances over 18 months.
    Foulon-Pinto G; Jourdi G; Perrin J; Abdoul J; Paris G; Gouin-Thibault I; Curis E; Lecompte T; Siguret V
    Int J Lab Hematol; 2021 Aug; 43(4):821-830. PubMed ID: 33369212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of thromboprophylactic doses of apixaban and rivaroxaban on coagulation and thrombin generation in association with total hip replacement.
    Helin TA; Virtanen L; Manninen M; Leskinen J; Leppilahti J; Joutsi-Korhonen L; Lassila R
    J Thromb Thrombolysis; 2017 May; 43(4):562-569. PubMed ID: 28315166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of direct oral anticoagulants on thrombin generation on Ceveron TGA.
    Pfrepper C; Behrendt LC; Bönigk H; Siegemund T; Metze M; Franke D; Petros S; Siegemund A
    Int J Lab Hematol; 2022 Feb; 44(1):193-201. PubMed ID: 34585540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
    Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
    Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgery with emicizumab prophylaxis for two paediatric patients with severe haemophilia A with inhibitors.
    Lockhart M; Tardy-Poncet B; Montmartin A; Noyel P; Thouvenin S; Berger C
    Pediatr Blood Cancer; 2021 Jul; 68(7):e29041. PubMed ID: 33851509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays.
    Kizilocak H; Marquez-Casas E; Malvar J; Carmona R; Young G
    Haemophilia; 2021 Sep; 27(5):730-735. PubMed ID: 34115433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay.
    Waters EK; Sigh J; Friedrich U; Hilden I; Sørensen BB
    Haemophilia; 2017 Sep; 23(5):769-776. PubMed ID: 28594458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue factor pathway inhibitor is the main determinant of thrombin generation in haemophilic patients.
    Chelle P; Montmartin A; Damien P; Piot M; Cournil M; Lienhart A; Genre-Volot F; Chambost H; Morin C; Tardy-Poncet B
    Haemophilia; 2019 Mar; 25(2):343-348. PubMed ID: 30690836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro.
    Minami H; Nogami K; Yada K; Ogiwara K; Furukawa S; Soeda T; Kitazawa T; Shima M
    J Thromb Haemost; 2019 Jan; 17(1):126-137. PubMed ID: 30444568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma.
    Grandoni J; Duretz V; Bonzo D; Evans S; Plantier JL
    Haemophilia; 2021 Mar; 27(2):321-328. PubMed ID: 33550714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A.
    Josset L; Leuci A; Janbain M; De-Wreede A; Desage S; Lienhart A; Bin V; Lebert D; Delavenne X; Dargaud Y
    J Thromb Haemost; 2024 Jul; 22(7):1857-1866. PubMed ID: 38583717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
    Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
    Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
    Wong PC; Jiang X
    Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.
    Semeraro F; Incampo F; Ammollo CT; Dellanoce C; Paoletti O; Testa S; Colucci M
    Thromb Res; 2016 Feb; 138():22-29. PubMed ID: 26826504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new era of treatment for patients with haemophilia A?
    Klamroth R
    Hamostaseologie; 2017 Aug; 37(3):216-218. PubMed ID: 27885373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.
    Song Y; Wang Z; Perlstein I; Wang J; LaCreta F; Frost RJA; Frost C
    J Thromb Haemost; 2017 Nov; 15(11):2125-2137. PubMed ID: 28846831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between plasma tissue Factor Pathway Inhibitor (TFPI) levels, thrombin generation and clinical risk of bleeding in patients with severe haemophilia A or B.
    Tardy-Poncet B; Montmartin A; Chambost H; Lienhart A; Frotscher B; Morange PE; Falaise C; Collange F; Dargaud Y; Toussaint-Hacquard M; Ardillon L; Wibaut B; Jeanpierre E; Nguyen P; Volot F; Tardy B
    Haemophilia; 2024 May; 30(3):693-701. PubMed ID: 38650319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.